Placebo-controlled study of the mite allergen-reducing effect of tannic acid plus benzyl benzoate on carpets in homes of children with house dust mite sensitization and asthma.
We studied the effect of a spray containing 1% benzyl benzoate, an acaricide, and 1% tannic acid ('Lowal'; a protein-denaturing substance), on concentrations of major allergens from house dust mite (HDM) species Dermatophagoides pteronyssinus and D. farinae (Der p 1 and Der f 1, respectively) in carpets. In a double-blind, placebo-controlled study with crossover design, 30 homes of children with HDM sensitization and asthma were included. All houses showed > or = 400 ng/g of Der p 1 + Der f 1 in carpet dust. The first treatment was performed on day 0 (group 1 active treatment, n = 15; group 2 placebo treatment, n = 15). After 2 and 8 weeks, dust samples were collected for quantification of mite allergens. After a 2-week washout period, the second treatment was performed (group 1 placebo treatment; group 2 active treatment). Again, carpet dust was collected after 2 and 8 weeks. Twenty-two of 30 families completed the trial: 14/15 in group 1 and eight of 15 in group 2. On day 0, there was no significant difference in mite allergen exposure between group 1 and group 2 (1,498 vs. 2,239 ng/g of Der p 1 + Der f 1, respectively). In group 1, the geometric mean for the difference of mite allergen concentration comparing day 0 and week 6 was 196 ng/g (95% CI: -7,161 and 8,401) for the first treatment (active) and 15 ng/g (95% CI: -1,079 and 1,292) for the second treatment (control). In group 2, the difference was 66 ng/g (95% CI: -398 and 1,515) for the first treatment (control) and 609 ng/g (95% CI: 186 and 9,264) for the second treatment (active). Comparing placebo and active treatment in total, there was a significant decrease following placebo treatment after 14 days (p = 0.026). After 8 weeks, active treatment was superior to placebo treatment (p = 0.049), but the allergen reduction achieved was < 20% (median 1,500 ng/g on day 0 vs. 1,250 ng/g after 8 weeks). We conclude that the slight mite allergen reduction on carpets achieved by the treatment with 'Lowal' is unlikely to achieve worthwhile clinical benefit either in the treatment of mite-sensitive patients or in primary or secondary prophylaxis.
Lau
Susanne
S
University Children's Hospital Charité, Humboldt University, Berlin, Germany. susanne.lau@charite.de
Wahn
Julia
J
Schulz
Gabriele
G
Sommerfeld
Christine
C
Wahn
Ulrich
U
D039741:Antigens, Dermatophagoides / Q000187:drug effects* / Q000276:immunology*; D060829:Arthropod Proteins; D001249:Asthma / Q000276:immunology*; D001565:Benzoates / Q000494:pharmacology*; D018592:Cross-Over Studies; D003546:Cysteine Endopeptidases; D004311:Double-Blind Method; D005430:Floors and Floorcoverings; D006801:Humans; D047348:Hydrolyzable Tannins / Q000494:pharmacology*; D007114:Immunization
D039741:Antigens, Dermatophagoides; D060829:Arthropod Proteins; D001565:Benzoates; D047348:Hydrolyzable Tannins; D003546:Cysteine Endopeptidases; C451162:Dermatophagoides pteronyssinus antigen p 1; C006723:benzyl benzoate